Harbour Investments Inc. Has $159,000 Stock Position in Theratechnologies Inc. (NASDAQ:THTX)

Harbour Investments Inc. increased its position in shares of Theratechnologies Inc. (NASDAQ:THTX) by 20.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,772 shares of the company’s stock after acquiring an additional 14,655 shares during the quarter. Harbour Investments Inc. owned 0.19% of Theratechnologies worth $159,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in THTX. Raymond James Financial Inc. acquired a new stake in Theratechnologies during the 4th quarter worth about $27,000. Wealthspire Advisors LLC boosted its holdings in shares of Theratechnologies by 39.0% during the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock worth $129,000 after purchasing an additional 20,000 shares during the period. Finally, National Bank of Canada FI boosted its holdings in shares of Theratechnologies by 29.4% during the third quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock worth $232,000 after purchasing an additional 42,435 shares during the period.

Analyst Upgrades and Downgrades

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a research report on Friday, February 14th.

Theratechnologies Trading Down 2.5 %

Shares of NASDAQ:THTX opened at $1.58 on Friday. The firm has a market cap of $72.65 million, a price-to-earnings ratio of -15.80 and a beta of 1.24. Theratechnologies Inc. has a 1 year low of $1.08 and a 1 year high of $2.18. The business has a fifty day simple moving average of $1.65 and a 200 day simple moving average of $1.48.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.